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Abstract 
 Lung neuroendocrine tumors (NET) are currently classified in resection specimens 
according to four histological categories, namely typical carcinoid (TC), atypical carcinoid 
(AC), large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SCC). 
Diagnostic criteria have remained unchanged in the 2015 WHO classification, which has 
ratified the wide acceptance and popularity of such terminology in the pathologists’ and 
clinicians’ community. A unifying umbrella of NE morphology and differentiation has been 
recognized in lung NET, which has pushed to enter an unique box of invasive tumors along 
with diffuse idiopathic pulmonary NE cell hyperplasia (DIPNECH) as a pre-invasive lesion 
with a potential towards the development of carcinoids. However, uncertainties remain in the 
terminology of lung NET upon small samples, where Ki-67 antigen could play some role to 
avoid misdiagnosing carcinoids as high-grade NE tumors. Epidemiologic, clinical and genetic 
traits support a biological three-tier over a pathology four-tier model, according to which TC 
are low malignancy tumors, AC intermediate malignancy tumors and LCNEC/SCC high 
malignancy tumors with no significant differences in survival among them. Inconsistencies in 
diagnostic reproducibility, troubles in the therapy of AC and LCNEC, and limitations to 
histology within the same tumor category argue in favor of a global re-thinking of lung NET 
where a grading system could play a role. This review outlines three main key-questions in 
the field of lung NET: a) unbiased diagnoses, b) the role of Ki-67 and tumor grading, and c) 
management of predictive markers. Answers are still inconclusive, thus additional research is 
required to improve our understanding on lung NET. 
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Approaching lung NET 
The new 2015 WHO classification on lung neuroendocrine tumors (NET) 
1
 has 
substantially confirmed the four widely-agreed upon histological variants crystallized in the 
two previous editions of 1999 
2
 and 2004 
3
, namely typical carcinoid (TC), atypical carcinoid 
(AC), large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SCC). 
Remarkably, in this 2015 edition, these tumors have been pushed to enter a unique box of 
NE proliferations by moving LCNEC from the all-inclusive chapter of large cell carcinoma, and 
adding diffuse idiopathic pulmonary NE cell hyperplasia (DIPNECH) as a pre-invasive lesion 
with a potential towards the development of carcinoids 
1
. There are several practical reasons 
why this traditional terminology of lung NET has been retained in the new 2015 WHO 
classification, which is the result of widely shared expert opinions according to the current 
state of the art 
1, 4
. The term carcinoid, either typical or atypical, has been gaining wide 
popularity and diagnostic awareness among pathologists and clinicians while valuable 
alternatives are still lacking 
1, 4
. Likewise, the other two histological variants, either LCNEC or 
SCC, are deemed to be full-blown high-grade carcinomas occurring in either pure or 
combined forms, which are almost relentlessly characterized by aggressive clinical behavior 
and dismal prognosis 
1, 4-8
. 
There is general agreement that this four-tired histological classification is consistent 
with an operational three-tier prognostic scheme on the basis of epidemiological (age, sex, 
smoking habit), genetic (association with MEN1 syndrome and several other gene pathways), 
clinical (lymph node and distant metastases, association with paraneoplastic syndromes, type 
and response to therapy) and behavioral traits, which results in progressive grades of 
biological aggressiveness 
1, 9-14
. Accordingly, TC is deemed to be a low-grade malignant 
tumor with longer life expectation and time to recurrence, AC an intermediate-grade 
malignant tumor with more aggressive clinical course, somewhat unpredictable clinical 
behavior and shorter time to recurrence, and LCNEC and SCC high-grade malignant tumors 
with dismal prognosis, challenging therapy options and, often, difficulties in reliably 
distinguishing from each others, either pathologically, genetically or clinically 
1, 4, 8, 14-19
. 
As a function of cell differentiation and in keeping with the recent European 
Neuroendocrine Tumor Society (ENETS) guidelines 
4
 and the current WHO classification 
1
, 
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TC and AC as a whole are considered well-differentiated NE tumors because of their 
resemblance to the normal cell counterpart of the NE diffuse system or pre-invasive lesions, 
such as DIPNECH, as opposed to LCNEC and SCC, which are thought to make up a poorly 
differentiated tumor group 
1, 20, 21
. As a matter of fact, TC and AC feature organoid growth 
patterns, typical to slight atypical cytology (even though they may uncommonly exhibit 
prominent nuclear pleomorphism) (Figure 1), absent to focal punctate necrosis, up to 10 
mitoses per 2 mm
2
 and consistent labeling for pan-NE markers, such as chromogranin A and 
synaptophysin, sometimes less intense and uneven in the setting of AC 
1, 4, 12, 14
. On the 
contrary, SCC and LCNEC show solid growth patterns, extensive/geographic necrosis, mitotic 
count higher than 10 mitoses per 2 mm
2
, and uneven labeling for pan-NE markers 
1, 4, 12, 14
. 
Cytological criteria are then used to split SCC from LCNEC, although there is a considerable 
morphologic overlap between them making this separation quite subjective and difficult to 
carry out, with disappointingly low inter-observer diagnostic reproducibility 
12, 15, 16, 22-25
. 
The molecular scenario of lung NET has been pushed to emerge by several studies 
confirming the assumption that there are two distinct groups in lung NET. As a matter of fact a 
dichotomous separation between low to intermediate malignancy tumors on the one hand 
(i.e., TC and AC) and high malignancy tumors on the other hand (i.e., SCC and LCNEC) is 
solidified by substantial differences in gene pathway alterations, levels of differentiation and 
cell derivation 
8, 12, 26-32
. Accordingly, it is not surprising that common genetic traits may be 
shared by each of these two broad tumor categories, with TC/AC on the one hand and 
LCNEC/SCLC on the other hand exhibiting major differences in the somatic mutation rates 
and engagement of diverse gene pathways 
8, 12, 26-33
. A further inherent molecular 
heterogeneity, however, is found within each histological variant on the basis of several 
functional and genetic biomarkers, which may identify different patient subsets with different 
prognosis 
31, 34-37
. 
All these assumptions suggest the opportunity to reevaluate lung NET keeping in 
mind that all lung NET are malignant, that the malignancy rate has to be quantified for clinical 
purposes of personalized therapy, and that malignancy depends on several biological and 
functional factors, among which a grading system specifically devised for the lung could play 
a pivotal role 
13
. The ultimate and ambitious goal is to improve our understanding in the field 
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of lung NET tumors, placing them into context for the best management practice of these 
patients. 
 
Designing the article 
A review of papers reported on the issues of lung NET with special reference to 
diagnosis, Ki-67, grading and predictive markers was performed until July 2015, taking 
advantage of a list of key questions for either subject. We limited our bibliography research to 
the English literature, apart from some historical papers published in other languages. Only 
full papers of peer-reviewed journals were considered. Research terms included carcinoid, 
typical, atypical, small cell, large cell, LCNEC, SCLC, intermediate, neuroendocrine, Ki-67, 
proliferation, grading, mitoses, count, necrosis, DNA, square millimeter, next generation, 
prognosis, survival, predictive factors, aggressiveness, therapy, targeted, sequencing, 
genome, exome, exon, genomic, landscape, portrait, whole, transcriptome, expression, high-
throughput, thymidylate synthase, fluoropyrimidine therapy, excision repair cross-
complementation 1 (ERCC 1), somatostatin receptors, mammalian target of rapamycin (m-
TOR), and prediction. This article was not designed to make up an exhaustive overview on 
the current knowledge about lung-NET, but rather to critically reappraise and rethink these 
tumors in light of emerging issues and questions, which often arise among physicians who 
treat these tumors daily within operating multidisciplinary teams. The ultimate goal was to 
focus on practical aspects of the fascinating world of lung-NET to answer practical questions. 
Specifically, we have herein developed three main key-questions, which clinicians could like 
to ask pathologists whenever facing lung NET. They are relative to the need: a) to have more 
precise and unbiased diagnoses; b) to unravel the role of prognostic factors with particular 
emphasis to Ki-67 labeling index and tumor grading; and c) to use predictive markers in the 
clinical management of these tumor patients. The following exposition will follow these three 
main key-questions, in light of recently published papers. 
 
Diagnosing lung NET 
 Diagnosis still remains the first but no longer the only task clinicians are requiring to 
pathologists whenever facing lung NET. Some entities proposed over time in the field of lung 
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NET may be considered milestones with direct and continuing integration to the current 
terminology, while other terms or taxonomy schemes are only a historical inheritance (at least 
according to recent guidelines 
4
 and WHO classification 
1
). Diagnostic criteria for SCC - as we 
still know and currently rely on - date basically back to Azzopardi’s publication of 1959 
38
, 
where the appellation of oat cell carcinoma reappraised the previous concept of small-celled 
sarcoma by Barnard of 1926 
39
. The term AC was introduced in 1972 by Arrigoni 
40
 taking 
advantage of necrosis, increased mitoses, disorganized architecture and cell atypia to 
enucleate lung carcinoid patients characterized by more aggressive clinical course from the 
preexisting category of bronchial carcinoid/adenoma as authored by Hamperl in 1937 
41
, who 
extended to the lung the entity initially recognized and described in the small intestine by 
Oberndorfer in 1907 
42, 43
. Subsequently, diagnostic criteria for AC were definitely outlined by 
Travis in 1998 
7
, which retained both name and defining features with no remarkable changes 
in the subsequent three WHO classifications of 1999 
2
, 2004 
3
 and 2015 
1
. LCNEC as high-
grade tumor intermediate behaviorally between AC and SCLC was authored by Travis in 
1991 
44
, which showed striking similarities to NE carcinoma of intermediate cell type 
described by Gould of 1983 
45
. In 1998, this entity was confirmed in its current diagnostic 
attributes 
7
 and inter-observer reproducibility 
6
, but survival rate was equaled to that of SCC. 
Many other classifications and terminologies have been proposed over time on lung 
NET, whose detailed examination is beyond the scope of the current paper, by either 
introducing a concept of tumor grading 
11, 13, 46-49
, applying different thresholds to current 
defining criteria 
50, 51
 or extending to these tumors the same defining criteria as those used in 
the gastroenteropancreatic tract 
21, 52-54
. These different proposals, however, have not gained 
wide acceptance yet because of the lack of clear clinical advantages over the last three WHO 
classifications on lung cancer, which represented the gold standard for these tumors. 
1-3
. 
Suffice to say that lung NET have maintained the same terminology and defining criteria of 
the past 16 years, making them popular among pathologists and clinicians and justifying their 
application to the current clinical management. However, the diagnostic inter-observer 
reproducibility among the diverse categories of lung NET still remains an unanswered 
question 
6, 15, 16, 23, 55-59
, as well as difficulties in identifying different patient subsets with 
different clinical behavior within the same histological variant or stage of disease, or in 
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correctly diagnosing non-resection specimens 
1, 4
. While it is reasonable that no classification 
is able to predict all exceptions, there are some open questions regarding the current 
taxonomy on lung NET, which we have been summed up in Table 1. 
It is well established that the diagnosis of lung NET is a stepwise process 
22
, 
according to which NE architecture is recognized at first and then tumors are divided into four 
diagnostic categories on the basis of the number of mitoses per 2 mm
2
 and the presence (and 
extent) of necrosis 
1, 4
. Additional criteria include the demonstration of pan-NE markers upon 
immunohistochemistry (IHC) to split LCNEC from large cell carcinoma with NE morphology or 
more conventional non-small cell carcinomas and a constellation of cyto-morphologic features 
to separate LCNEC from SCLC 
1
. A synopsis of diagnostic criteria in resection specimens as 
outlined by the recent 2015 WHO classification is reported in Table 2, while representative 
pictures of the four tumor categories according to these criteria are depicted in Figure 2. 
Despite the presence of a general unanimous separation between the two ends of 
the lung NET spectrum, i.e. TC and SCLC, at least in surgical specimens, major diagnostic 
concerns emerge for adjacent categories whenever addressing boundary or gray zone 
tumors where the subjective application of defining criteria (mainly mitoses and necrosis) may 
encounter difficulties in their ultimate diagnostic attribution, i.e. TC vs. AC, AC vs. LCNEC, 
and LCNEC vs. SCLC 
6, 15, 16, 23, 55-59
. Detailed studies on the clinico-pathologic features of 
these boundary or gray zone lung NET are still lacking, but it is well known that AC showing a 
number of mitoses comprised between 6 and 10 per 2 mm
2
 run a worse clinical course 
60
, and 
that on the contrary about 15-20% of SCC or LCNEC patients experience long survival 
7, 10, 13, 
59, 61, 62
. There are a number of issues accounting for inconsistency between morphology and 
clinical behavior 
6, 12, 63
. Difficulties in recognizing mitoses and necrosis in the group of TC and 
AC 
55
 and variability in assessing cell size and cytological features in the group of LCNEC and 
SCLC 
6, 15, 16, 23, 57
 may explain inconsistencies in the diagnostic reproducibility of lung NET. 
Additional criteria, such as the labeling for mitosis-specific marker anti-phosphohistone H3, 
have been proposed to objective subjectivities in mitosis assessment 
64
, but the experience in 
still limited and there are no objective methods to account for tumor cell necrosis. The use of 
Ki-67 antigen could simplify this evaluation of proliferation activity, but overlap existing 
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between adjacent tumor categories and quantification modalities 
12, 29
 prevented to exploit this 
marker as defining criterion of lung NET according to current guidelines 
1, 4
.  
Recognition of lung NET, especially in non-resection samples, is recommended by 
using IHC for pan-NE (synaptophysin, chromogranin A, hASH1) and epithelial markers 
(cytokeratin pools), in keeping with recent guidelines and classifications 
1, 4
. Worth mentioning 
is the application of always-negative-markers, such as high molecular weight cytokeratins 
65, 
66
 or p40 
67
, whereas p63 may be consistently expressed by SCC 
68
. It should be kept in mind 
that many nuclear transcription factors used for differentiating NET arising in diverse 
anatomical sites, such as TTF-1, Islet-1, PAX-8 and CDX2, hold true for well-differentiated 
tumors only, i.e. TC and AC, as LCNEC and SCC can be associated with aberrant and 
illegitimate expression of these markers regardless of their origin (Figure 3). 
 
Unraveling Ki-67 and tumor grading 
As outlined above, current criteria for lung NET basically include mitosis count and 
necrosis 
12
, whilst tumor architecture, cell atypia, vascular invasion, lymph node metastases 
or immunohistochemistry profile do not play any role in this separation 
14, 17
. However, some 
controversies still persist in their diagnostic reproducibility, so that searching for additional 
criteria more related to behavioral traits is clinically warranted. 
Ki-67 antigen has been largely studied in lung NET 
12, 25, 29, 69
, with several features 
regarding technical issues, evaluation of results, diagnostic role, prognostic role (including 
tumor grading), and predictive role in therapeutic decisions being recently reviewed 
69
. There 
are different options to quantify Ki-67 antigen in lung NET (the product of MKI67 gene 
mapping to 10q26.2 gene acting as a non-histone nuclear protein involved in all active stages 
of the cell cycle, but not in resting cells), most often carried out upon immunohistochemistry 
by using the clone MIB-1 and expressed as the percentage of positive tumor cells (labeling 
index, LI), i.e. manual counting, digital image analysis or eyeball estimation 
69
. Most published 
investigations agreed on the opportunity of measuring Ki-67 LI in hot spot areas, taking into 
account all nuclear signals after visual scrutiny of the entire tumor area 
69
. This would apply 
especially to TC or AC, whereas Ki-67 decoration is usually much more uniform in high-grade 
NE tumors. For practical purposes, Ki-67 LI should be calculated in surgical specimens by 
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counting at least 2000 consecutive tumors cells in hot spot fields at 40x magnification or 2 
mm
2
 for consistency with the histological classification, possibly in the same tumor areas as 
those used for assessing mitotic count 
69
. In biopsy or cytology samples, in which the number 
of tumor cells may be lower than 2000 or the 2-mm
2
 criterion not necessarily met, it could be 
reasonable to calculate Ki-67 LI on all tumor cells. For experienced pathologists, however, 
manual counting of Ki-67 LI upon visual inspection or eyeball estimation differs little from 
more sophisticated, time- consuming, or cumbersome methods 
13, 70
. Although there are 
significant differences in the mean/median thresholds of Ki-67 LI amongst TC, AC, LCNEC 
and SCC 
61, 62, 69, 71-74
, some overlap existing between adjacent tumor categories prevented to 
establish a decisional role to this marker relative to histological classification 
1, 17
 simply 
because mitoses, necrosis and Ki-67 antigen look at different biological phenomena 
69
, albeit 
they are somewhat related to each other in terms of overwhelming behavioral impact 
29
. 
Reproducibility studies on Ki-67 LI assessment revealed encouraging results 
56, 75
, with less 
than 1.5% of variability 
75
 and an out-performance of Ki-67 LI over mitotic count with regard to 
inter-observer agreement 
56
. 
Ki-67 LI has a major value in distinguishing TC and AC from high-grade NET 
71, 73, 74
, 
especially when small crushed biopsy samples or cytology are dealt with (with a practical cut-
off point of 25% to operate this distinction) 
12, 13, 71, 73, 74
, as well as in differentiating between 
lower and higher malignant NE tumors in resection specimens of TC and AC (with cut-off 
thresholds ranging from 4% to 5%) 
13, 37, 54, 75-78
 in keeping with pancreatic NE tumors 
79, 80
, 
albeit sometimes with a non-independent value upon multivariate analysis 
75
. Although 
conceptually reasonable, few studies have so far addressed a role of Ki-67 LI in the 
prognostic stratification of poorly differentiated NE tumors in the lung 
13
, at variance with what 
has been proposed in other endocrine organs, such as the pancreas 
81, 82
. 
Tumor grading is a way to unravel the inherent aggressiveness of tumors exactly as 
the temperature correlates with the thermal energy of a body according to its average status 
of molecular agitation. Just like temperature, grading should be an intensive property of 
tumors independent of, albeit correlated with, tumor stage. In other words, grading would 
define the level of biological recruitment of tumors, correlated with but not completely 
overlapping with cell differentiation, which alone cannot exhaustively anticipate biological 
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behavior of tumors. As a matter of fact it is possible to diversify subsets of patients with 
different life expectation in the histological categories of lung NET 
32, 35, 36, 83
. This is the 
reason why grading systems based on the histological definition of disease may be not 
completely satisfying to take operational decisions in the clinical management of patients, 
especially in tumors where defining histological criteria are broader, such as AC or LCNEC 
29
. 
Grading of lung NET according to histology/cell differentiation is inherently present in 
the current WHO classification scheme 
1
. Accordingly, TC is low-grade malignant, AC 
intermediate-grade malignant, and LCNEC and SCLC high-grade malignant NET 
1, 4, 11, 46, 48
. 
In particular, SCC and TC are so agreed-upon tumor entities in the lung to seem too reductive 
to simply call them G3 and G1 tumors, respectively. However, establishing a grading system 
in lung NET independent of histology could be clinically warranted in individual tumor patients 
for the personalized therapy requirements, in keeping with the lesson of GEP-NET. Naturally, 
this grading system should rely on different defining criteria in the lung compared to GEP-
NET or other anatomical locations, as there are profound differences in biological behavior for 
tumors arising in different sites 
29, 80, 84-86
. Such a system should hopefully be independent of 
staging to take clinical decisions also in the metastatic setting of disease in accordance with 
the biological characteristics of tumors. An innovative grading method in resection specimens 
has recently been proposed for lung NET, which jointly included Ki-67, mitotic rate and 
necrosis, each parameter being further tired according to three different expression levels 
independent at multivariate analysis (Table 3) 
13
. In particular, G1 tumors were defined if at 
least 2 out of 3 parameters were at the level 1; G2 if at least 2 out of 3 parameters were at the 
level 2; and G3 if at least 2 out of 3 parameters were at the level 3. The combined 
assessment of these three parameters outperformed each individual parameter in predicting 
patient overall survival, resulting in a G1 to G3 grading system showing minimal overlap of 
95% confidence intervals among these three defining categories. Interestingly, all TC 
clustered into the G1 category whilst a small fraction of SCC and LCNEC were classified into 
the G2 category in keeping with the clinical observation that a small fraction of these patients 
pursues an unexpected less aggressive clinical course despite histological diagnosis 
36, 61, 62
. 
Importantly AC were split into all the three tumor grades reflecting the inherent behavioral 
heterogeneity of AC, some of which behave very similarly to TC whereas others are much 
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more aggressive, not diversely from poorly differentiated lung NET 
60
. These findings are 
likely to reflect the subjective interpretation of AC vs. TC or LCNEC when morphology is the 
only discriminating factor 
15, 16, 55
. Certainly many efforts will be needed for validating this 
grading proposal in lung NET by accruing independent tumor series in resection specimens, 
as well as for setting up a reliable grading system in small samples, which often are the only 
available material at the time of the initial diagnosis or in tumor metastases, where grading 
tumors could have clinical relevance 
4
 just like in GEP-NET 
84-86
. 
 
Predicting in NET 
 According to recent guidelines, no molecular tests should currently be routinely 
carried out in lung NET, unless specifically required by study protocols (Level of Evidence 4; 
Grade of Recommendation C) 
4
. However, an increasing body of knowledge is accumulating 
in lung NET about biomarkers with predictive value, which could modify the therapy of these 
tumors in near future. This holds true especially for TC and AC where treatment, when non 
directly surgical (as mainly happens), relies on multimodality approaches or non-conventional 
drugs, whilst LCNEC and SCLC are generally cured by exclusive chemo-radiotherapy 
87, 88
. 
In this setting of predictive biomarkers, Ki-67 LI does not play a decisive role in lung 
NET beyond refining better diagnostic recognition in demanding cases, for instance when 
occurring severe crush artifacts in small tissue samples 
71
. Ki-67 antigen is independent of or 
weakly associated with thymidylate synthase expression, an enzyme involved in DNA 
synthesis whose presence acts as a resistance factor to fluoropyrimidine therapy in tumors, 
including NET 
89
, as well as with excision repair cross-complementation 1 (ERCC 1) 
expression, a resistance factor against platinum-based chemotherapy in lung cancer 
90
, or 
mammalian target of rapamycin (m-TOR) signaling activation pathways, an attractive target 
for inhibitors such as everolimus 
61
. Thus far, no randomized clinical trials have documented 
that establishing Ki-67 LI in lung NE tumors may help to guide the subsequent therapy, just 
like in NSCLC 
91
. 
 In lung NET, there are several potential predictive factors, which could become 
eligible for clinical trials, on which it is warranted to accumulate more information for better 
personalizing therapy 
92
, including antifolate chemotherapy, somatostatin receptors, m-TOR 
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signaling pathway molecules and a miscellaneous of other factors. According to the lesson of 
tamoxifen in breast cancer 
93
, it has been demonstrated that the thresholds of thymidylate 
synthase evaluated by adopting either mRNA quantitative PCR 
89
 or semiquantitative protein 
expression upon IHC 
94
 were significantly higher in LCNEC and SCC than AC and TC or 
NSCLC indicating a different level of responsiveness to fluoropyrimidine therapy with longer 
time to progression of 5-fluorouracil-treated lung NET patients with lower expression of this 
biomarker 
89
. Somatostatin receptors are well-known targets for analogue drug therapy in 
GEP-NET 
95, 96
, but an emerging role is playing also in the control of non-surgical cases of 
well-differentiated lung NET due to their anti-proliferation activity and hormone secretion 
inhibition 
4, 97
. Somatostatin receptors can be easily assayed by IHC on tumor sections and a 
reliable scoring system has also been devised, which accurately correlates with in vivo 
imaging upon octreoscan 
62, 98
, opening the way to its routine use especially in the setting of 
non-operable lung NET 
99
. Targeting m-TOR pathway with specific inhibitors, such as 
everolimus, in lung well-differentiated NET results in anti-proliferative activity likely due to 
reduction of VEGF secretion and IGF1 signaling inhibition 
100
. Molecules involved in the 
downstream m-TOR activation pathway, such as phosphorylated m-TOR, AKT, p70S6K and 
ERK1/2 (MAPK3/1) 
101
, can be all easily assayed by IHC upon tumor tissue sections 
61
. 
Concurrent inactivation of m-TOR and PI3K pathways (for instance by using dual PI3K/mTOR 
inhibitor NVP-BEZ235) gave rise to more potent effects than everolimus alone in reducing the 
proliferation of human bronchial carcinoid cells, with resistant tumor cells displaying lower 
levels of mTOR, p70S6K, AKT and ERK1/2 
101
. These findings indicate that looking for these 
proteins may be useful to predict sensitiveness for high protein levels or resistance for low 
protein levels to synergic m-TOR and PI3K/m-TOR inhibitor treatment in well-differentiated 
NE proliferations, including carcinoids and DIPNECH 
102, 103
. The pathway of m-TOR in lung 
NET is also related to energy and metabolism regulation by expression of GLUT1 and LAT1, 
the former being prevalent in high-grade NET with an inverse correlation with m-TOR and 
somatostatin receptor type 2 expression, the latter being prevalent in well-differentiated NET 
with direct correlation with somatostatin receptor type 2, survivin and angiopoietin II 
expression, independently of glucose or oxygen availability (Volante et al, manuscript in 
preparation). Additional molecular targets potentially useful in lung NET include c-
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MET/phospho-cMET up-regulation via PAX5 activity in AC, SCC and LCNEC, where co-
inhibition produced a synergistic effect in killing tumor cells, probably related to paxillin 
inactivation, which is a downstream target of activated c-MET involved in cell motility and 
tumor spread 
104
. MET mutations are relatively rare in SCLC and others lung NET, they affect 
the juxtamembrane domain and are of no functional relevance as they do not influence c-Met 
phosphorylation, regardless of tyrosine kinase inhibitor treatment 
105
. LCNEC patients present 
with variable c-KIT, Her-2/neu, VEGF PDGFR-alpha, PDGFR-beta protein overexpression but 
with no c-KIT or EGFR gene mutations or amplification 
106
, suggesting a negative prognostic 
factor for c-KIT expression 
107, 108
 and a potential therapeutic effect for anti-VEGF-, anti-c-KIT- 
and possibly anti-HER2-targeted agents in the treatment of these tumors 
108, 109
. The same 
LCNEC show preferential expression of potential markers for cancer stem cells, including 
aldehyde dehydrogenase 1 family member A1, aldo-keto reductase family 1 members C1 and 
C3 and CD44 antigen, which could have diagnostic and prognostic implications in these 
tumors 
110
. The differential expression of CD44, orthopedia transcription factor and menin, the 
product of MEN-1 gene, and 11q22.3-q25 deletion in TC and AC and of aurora B kinase and 
surviving in high-grade NE carcinomas may comprise therapeutic targets for these tumors 
31, 
83, 111
, as well as identify subpopulations of patients within each tumor category with different 
life expectation allowing a better risk stratification for therapy purposes 
31, 35, 83
. A better 
understanding of the entire landscape of molecular alterations in lung NET affecting either 
genetic or epigenetic mechanisms would hopefully lead to a molecular classification in part 
heralded by recent next generation sequencing studies 
26, 28, 112, 113
, where predictive 
biomarker assessment in the diverse tumor categories would help to identify different patient 
subpopulations suitable for personalized therapies. 
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Conclusion 
 Lung NET comprise a quite heterogeneous cluster of human malignancies with 
profound differences in the epidemiologic, genetic, pathologic and behavioral characteristics, 
which can cause a conundrum to the biological understanding of these lesions. Through an 
enlightened re-thinking of lung NET, pathologists should provide clinicians with better 
diagnostic refining of the diverse categories of lung NET with closer adherence to the clinical 
reality by means of an innovative concept of tumor grading. Additionally, they should clarify 
the meaning of Ki-67 LI in the practical clinical management of patients and offer expertise 
and knowledge about molecular, genetic and predictive (therapeutic) factors that could be 
meaningful for clinical purposes. The final goal is to unravel the inherent complexity of lung 
NET to finally increase our options of therapy in these tumor patients. 
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Figure legends 
 
Figure 1. Typical carcinoid of the lung (no necrosis; 1 mitosis/2 mm
2
) with nuclear 
pleomorphism in tumor cells: this feature is not per se diagnostic of atypical carcinoid. 
 
Figure 2. Representative pictures of lung NET are shown according to the current 2015 WHO 
classification on resection specimens. Typical carcinoid is composed of trabecular 
arrangement of polygonal tumor cells with no necrosis and one mitotic figure only per 2 mm
2
 
(A), sometimes featuring spindle cell appearance especially in peripheral lung location (B). 
Atypical carcinoid exhibits at least 2 mitoses per 2 mm
2
 and/or punctate necrosis (C), 
whereas large-cell neuroendocrine carcinoma shows organoid architecture with extensive 
necrosis (D), plentiful mitoses and with peripheral palisading (E). In turn, small cell carcinoma 
presents with small-sized tumor cells with very scant cytoplasm and innumerable mitotic 
figures (F). 
 
Figure 3. This case of small cell carcinoma (A) showed high Ki-67 labeling index (B), faint 
and punctate positivity for cytokeratin pool (B, inset), strong and diffuse cytoplasmic 
decoration for synaptophysin (C) and scattered tumor cells positive for chromogranin A (C, 
inset). Unexpectedly, there was nuclear staining for transcription factors such as CDX-2 (D) 
and Islet-1 (E), whereas TTF-1 was diffusely positive as in most of these tumors (F).
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